Cell>Point announced today that it was awarded March 15, 2011 the North American SPECT Radiopharmaceuticals Technology Innovation Award by Frost & Sullivan.
CENTENNIAL, Colo., June 23, 2009 – Cell>Point today announced that the U.S.P.T.O. approved its Beta Cell Technology U.S. patent application (App. No. 10/942,615). Cell>Point’s Beta Cell Technology is currently in preclinical testing at The University of Chicago Medical Center for imaging Type I Diabetes.
CENTENNIAL, Colo., June 18, 2009 – Cell>Point is pleased to announce that Steve Hanely has joined our Board of Advisors. Mr. Hanley is a former President of the Global Imaging Division of Covidien . Mr. Hanley earned his MBA and BS, Business Administration from Marquette University.
CENTENNIAL, Colo., September 11, 2008 – Cell>Point is pleased to announce that Eric Kurzweil, M.D., MBA has joined our Board of Advisors. Dr. Kurzweil is currently President of the Rocky Mountain Region of Pediatrix. Pediatrix, a $2.63 billion market cap company listed on the NYSE:PDX which includes more than 900 physicians nationwide. Dr. Kurzweil received his undergraduate degree from Harvard University and his medical degree from the University of Miami School of Medicine. Dr. Kurzweil earned his master’s degree of business administration from the University of Colorado.
CENTENNIAL, Colo., July 1, 2008 – Cell>Point announced today that it has established a subsidiary in the Netherlands, Cell>Point Netherlands BV. Cell>Point plans to expand its operation in Europe including financial partners and European clinical trial sites for its Phase III clinical trials in 99mTc-EC-G.
CENTENNIAL, Colo., January 25, 2008 – Cell>Point, L.L.C. today announced that it will present at the Wachovia 2008 Healthcare Conference, which will be held January 29-31, 2008, at The Langham Hotel in Boston, Mass. Cell>Point will present Thursday, January 31 at 1:00 pm (Eastern Time) in the Palmer Room.
CENTENNIAL, Colo., September 12, 2006 Cell>Point today announced F. David Rollo, M.D., Ph.D. has joined the company as President. Dr. Rollo was formerly Chief Medical Officer of Philips Medical Systems, a global leader in diagnostic imaging systems and healthcare information technology solutions.
Cell>Point has licensed five radiopharmaceutical technology platforms from The University of Texas M.D Anderson Cancer Center. Continue reading
CENTENNIAL, Colo., June 1, 2006 -Cell>Point today announced it plans to start a Phase II clinical trial to evaluate the effectiveness of its 99mTc-EC-DG (Technetium-99m-Ethylenedicys-teine-Deoxyglucose) in diagnosing the presence of viable tissue in regions of the myocardium damaged by myocardial infarction or chronic coronary artery disease. Continue reading
ENGLEWOOD, Colorado – November, 8, 2005 – Cell>Point was named Biotech “Rising Star of the Year” by the Colorado BioScience Association.
HOUSTON, Texas – June 3, 2005 – Cell>Point obtained the worldwide patent and technology license to Oligosaccharide Conjugates for Dual Imaging and Radio/Chemotherapy developed at The University of Texas M. D. Anderson Cancer Center. This novel technology is facilitating the development of combination modality diagnostic imaging agents and new combination radio/chemotherapeutic agents for use in oncology, cardiology, neuroendocrinology and infectious diseases. The imaging agents will be used in SPECT/CT and PET/CT. These combination agents should shorten the time the patient has to spend in the imaging session. This dual agent technology is also facilitating the development of targeted radio/chemotherapeutic agents. The objective is for the medical oncologist/radiation oncologist to be able to administer targeted radiotherapy and chemotherapy at the same time in a single dose to the patient. Since this technology also uses Cell>Point EC Technology, the combination of the two technologies should make a very versatile imaging/therapy platform.
ENGLEWOOD,Colorado-May20,2005-Cell>Point was featured in the following Aunt Minnie article
Biotech firm Cell>Point sees promise for oncology SPECT 1/20/2005 By: Kate Madden Yee
Since PET imaging was introduced in the 1990s, its advocates have slowly but surely established a place for the technology, so much so that PET is now considered by many to be the best modality for functional oncology imaging. Continue reading